You know Taxus is having competitive problems when BSX is still touting its benefits relative to bare-metal stents, as in this PR: <a href="http://finance.yahoo.com/news/Study-Shows-Superior-Efficacy-prnews-3977871875.html?x=0&.v=1" rel="nofollow" target="_blank">http://finance.yahoo.com/news/Study-Shows-Superior-Efficacy-prnews-3977871875.html?x=0&.v=1</a>